+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P13464(GLIS1 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P13464(GLIS1 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The GLIS1 antibody is a research tool designed to detect and analyze GLIS1 (Gli-similar 1), a member of the GLIS subfamily of Krüppel-like zinc finger transcription factors. GLIS1 regulates gene expression by binding to specific DNA sequences and plays critical roles in embryonic development, cellular reprogramming, and tissue homeostasis. It is notably involved in maintaining pluripotency in stem cells and facilitating induced pluripotent stem cell (iPSC) generation, often working synergistically with factors like OCT4. SOX2. and KLF4. Dysregulation of GLIS1 has been linked to developmental disorders, fibrosis, and cancers, where its aberrant expression may drive pathological processes such as uncontrolled cell proliferation or epithelial-mesenchymal transition.

GLIS1 antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study its expression patterns, subcellular localization, and interactions in various biological contexts. These antibodies are essential for elucidating GLIS1's role in signaling pathways, such as TGF-β and Wnt, and its cross-talk with other transcription factors. Researchers also employ GLIS1 antibodies to explore its potential as a therapeutic target, particularly in diseases associated with fibrosis or tumor progression. Validation of antibody specificity, often through knockout controls or peptide-blocking assays, is crucial due to structural similarities among GLIS family members. Commercial GLIS1 antibodies are typically raised in rabbits or mice, targeting specific epitopes within its N-terminal or zinc finger domains.